March 03, 2023
Amgen and Teva told a Delaware federal court it has the authority to grant their request for an immediate appeal of a prior judge's refusal to toss a case accusing them of cutting an illegal deal to remove a generic calcium control drug from the market.
March 14, 2022
The Delaware federal judge charged with overseeing sprawling multidistrict litigation accusing Amgen and Teva Pharmaceuticals, among others, of hatching an illegal deal to remove a generic calcium control drug off the market has sorted through dozens of claims and decided which ones are fit to proceed.